简介：目的：探讨针刺疗法结合康复对围产期脑损伤高危儿智力及运动发育的影响。方法：对97例经新生儿重症监护室（NICU）救治存活的围产期脑损伤高危儿，按患儿家长意愿划分两组，针刺组53例，采用针刺结合康复治疗。对照组44例，采用常规育儿方式。两组均系统跟踪随访至2周岁，于6、12、24月龄时由专人定期采用婴幼儿智能发育量表进行智能测定。结果：针刺组在2岁时智力发育指数（MDI）与运动发育指数（PDI）分别高于对照组14．69、9．82分；针刺组智能异常率为15．1％，明显低于对照组40．9％，两组间差异具有统计学意义（χ2=8．1659，P〈0．01）。结论：针刺结合康复能有效地促进围产期脑损伤高危儿智力及运动发育，是改善预后、减少伤残率．提高患儿生存质号自勺有效丰段．

简介：无

简介：无

简介：AbstractThe NOD-like receptor protein 3 (NLRP3) inflammasome is a key regulator of the host’s immune response, and many immune and metabolic disorders are linked to its activation. This review aimed to investigate and clarify the relationship between this inflammasome and high-risk reproductive disorders. Papers cited here were retrieved from PubMed up to August 2020 using the keywords "NLRP3" or "NALP3" , "caspase-1" , "endometriosis" , "gestational diabetes" , "interleukin (IL)-18" , "IL-1β" , "pre-eclampsia (PE)" , "preterm birth" , "polycystic ovarian syndrome (PCOS)" , "recurrent spontaneous abortion (RSA)" , and combinations of these terms. The results show that NLRP3 inflammasome is associated with various high-risk reproductive disorders and many inflammatory factors are secreted during its activation, such as IL-1β induced during the development of endometriosis. PCOS is also associated with activation of the NLRP3 inflammasome, especially in overweight patients. It also participates in the pathogenesis of RSA and is activated in fetal membranes before preterm birth. The placentas of pregnant women with PE show higher expression of the NLRP3 inflammasome, and gestational diabetes mellitus occurs simultaneously with its activation. Current evidence suggest that the NLRP3 inflammasome plays an important role in female reproductive disorders. New treatment and management methods targeting it might help reduce the incidence of such disorders and improve neonatal outcomes.

简介：对在中间风险、高风险的子宫内膜的癌症的辅助治疗的实践和结果的现在的模式客观。有从1999～2006的中间风险、高风险的子宫内膜的癌症的224个女人上的方法回顾的数据被考察。所有病人经历了外科的阶段。辅助治疗的模式，加化疗由骨盆的放射疗法，化疗，和放射疗法组成，被估计。3年、5年的疾病特定的幸存(决策支持系统)率用Kaplan-Meier方法被计算。结果处于5年的决策支持系统率的差别在辅助的组和非辅助的组之间是统计上重要的(80.65%对63.80%，P=0.040)。在经历了辅助治疗的110个高风险的病人，两5年的决策支持系统率和周期性的率独自与放射疗法相比在联合放射疗法和化疗组是显著地不同的，化疗独自组织(决策支持系统率，P=0.049；周期性的率，P=0.047)。在经历了辅助治疗的83个中间风险的女人，在联合放射疗法之中处于5年的决策支持系统率和复发率没有重要差别，化疗，独自一个的放射疗法和化疗独自组织(决策支持系统率，P=0.776；周期性的率，P=0.937)。加化疗的结论辅助放射疗法在高风险的子宫内膜的癌症病人独自与独自一个的放射疗法和化疗相比与更高5年的决策支持系统率和更低的复发率被联系。有中间风险的子宫内膜的癌症的病人可能不是可能的得益于辅助联合放射疗法和化疗。

简介：Asmanycountrieshaveenteredanewperiodofadjustmentanddevelopmentalcompetitioninthewakeofthefinancialcrisis,someprofoundchangesandtransformationshaveinevitablytakenplaceintheinternationalstrategicconfigurationandtheinternationalorder.AstheconnotationsandconditionsofChina’snew

简介：Primarycentralnervoussystemlymphoma(PCNSL)isararedisorderthat,in95%ofcases,representsdiffuselargeB-celllymphoma.Assuch,makinganaccuratediagnosisisimportant.Atpresent,stereotactic-guidedbiopsyisarecognizedmethodofchoicefortissueanalysis.However,thediagnosticwork-upforhigh-riskpatientsisdeterminedbytheirperformancestatus.Here,wereportacaseofPCNSLinahigh-riskpatient,forwhomdiagnosiswasestablishedbycerebrospinalfluidcytologyandflowcytometry,whichsignificantlyshortenedadiagnosticwork-upperiodandallowedfortheimmediatetreatmentofthepatient.

简介：无

简介：AbstractBackground:Family clustering of esophageal cancer (EC) has been found in high-risk areas of China. However, the relationships between cancer family history and esophageal cancer and precancerous lesions (ECPL) have not been comprehensively reported in recent years. This study aimed to provide evidence for identification of high-risk populations.Methods:This study was conducted in five high-risk areas in China from 2017 to 2019, based on the National Cohort of Esophageal Cancer. The permanent residents aged 40 to 69 years were examined by endoscopy, and pathological examination was performed for suspicious lesions. Information on demographic characteristics, environmental factors, and cancer family history was collected. Unconditional logistic regression was applied to evaluate odds ratios between family history related factors and ECPL.Results:Among 33,008 participants, 6143 (18.61%) reported positive family history of EC. The proportion of positive family history varied significantly among high-risk areas. After adjusting for risk factors, participants with a family history of positive cancer, gastric and esophageal cancer or EC had 1.49-fold (95% confidence interval [CI]: 1.36-1.62), 1.52-fold (95% CI: 1.38-1.67), or 1.66-fold (95% CI: 1.50-1.84) higher risks of ECPL, respectively. Participants with single or multiple first-degree relatives (FDR) of positive EC history had 1.65-fold (95% CI: 1.47-1.84) or 1.93-fold (95% CI: 1.46-2.54) higher risks of ECPL. Participants with FDRs who developed EC before 35, 45, and 50 years of age had 4.05-fold (95% CI: 1.30-12.65), 2.11-fold (95% CI: 1.37-3.25), and 1.91-fold (95% CI: 1.44-2.54) higher risks of ECPL, respectively.Conclusions:Participants with positive family history of EC had significantly higher risk of ECPL. This risk increased with the number of EC positive FDRs and EC family history of early onset. Distinctive genetic risk factors of the population in high-risk areas of China require further investigation.Trial registration:ChiCTR-EOC-17010553.

简介：这研究的目的是在为前列腺癌症经历了激进的前列腺切除术(RP)的人关于瘤攻击性调查耐心的年龄的预示的意义。在这研究，我们考察了没有neoadjuvant或辅助治疗，在我们的机构收到了RP并且被跟随在上面的743个病人的记录为>；2年手术后地。为我们的分析，病人根据年龄被划分成二个组：更年轻(<；60年)并且更旧(≥；60年)。通过uni-和multivariate分析，包括生物化学的没有复发的幸存，与耐心的年龄，各种各样的clinicopathological参数的协会在所有病人之中被评估，并且病人根据他们的D'Amico风险分类被成层。在所有题目之中，更年轻(n=126)并且更旧(n=617)病人们没关于病理学的参数和生物化学的没有复发的幸存(P=0.288)显示出重要差别。为高风险的组(n=206)，更年轻的病人比更老的病人(P=0.017)有生物化学的没有复发的幸存追随者外科的更低的率，尽管没有重要差别关于在二个年龄组之间的各种各样的已知的预示的参数被观察。另外，multivariate分析表明年龄是在高风险的组(P=0.003)之中的生物化学的没有复发的幸存的一个独立预言者。我们的结果证明相对更年轻的病人与他们后面的RP为前列腺癌症执行了的更旧的对应物相比有可比较的生物化学的结果。在有高风险的疾病的病人之中，然而，更年轻的病人与更老的病人相比有更坏的生物化学的结果追随者RP。

简介：无

简介：瞄准：到生命(QoL)的健康相关的质量上的现在的初步的结果，联系前列腺的症状和有在高风险的前列腺癌症(PCa)的雄激素剥夺治疗(ADT)的前列腺(TCSAP)的targeted-cryosurgical脱离的治疗学的效果病人。方法：有高风险的PCa特征的34个人经历了TCSAP，并且ADT被增加改进治疗结果。高风险的参数被定义为前列腺特定抗原(PSA)=或>100ng/mL，或格利森20=或>8，或两。为生活问询表核心的癌症质量的研究和治疗的欧洲组织的泌尿生殖器的组(EORTCQLQ-C30)30与prostate-cancer-specific模块(QLQ-PR25)被用于评估病态，PSA层次每3个月被记录。PSA失败被定义为无能到达0.4ng/mL或更少的一个天底。结果：尽管它不是统计上重要的，全球健康地位分数与ADT在TCSAP以后增加了。为五功能的规模的分数也成为了更高的术后疗法。最突出的症状术后疗法是性机能障碍，由处理相关、刺激性的voiding症状列在后面。结论：有ADT的TCSAP看起来除了性机能障碍与高QoL最低限度地侵略。在任何结论能在PCa的治疗在这种有希望的新治疗学的形式的功效上被做以前，PSA数据和幸存的长期的后续是必要的。

简介：Objectives:TodescribeandanalyzeHIV/AIDS/STD-relatedhighriskbehaviorsandaffectingfactorsofmenwhohavesexwithmen(MSM)inmainlandChina~Methods:426self-administeredorinterview-basedquestionnairescollectedfromMSMwereanalyzedwithSPSSorSASSystems.Results:OftheMSM,four-fifthshadengagedinoral-genitalintercourse,abouthalfhadengagedinanalintercourse,andinthepastyearmorethantwo-fifthshadcasualsexualpartner(s).Veryfewmaintainedmonogamoussexualrelationships,andnearlyhalfalsohadintercoursewithwomen.Onefourthhadpreviouslybeendiagnosedwithavenerealdiseases.OneHIV+individualwasfoundamongthe40whoreportedhavingbeentestedforHIV.Onlytwomenconsistentlyusedcondomsamongtheone-thirdwhohadeverusedcondoms,despitealmostuniversalknowledgeofHIVanditstransmission.Conclusions:MSMinmainlandChinaareverysexuallyactive,highlightingthepossibilityofaseriousHIVepidemicthatmaybedirectlyspreadtothefemalepopulation.However,AIDSinterventionstargetingMSMfacesevereobstructionsresultingfromculturalbiasandotherfactors.

简介：

简介：AbstractImportance:131I-metaiodobenzylguanidine (131I-mIBG) has a significant targeted antitumor effect for neuroblastoma. However, currently there is a paucity of data for the use of 131I-mIBG as a "front-line" therapeutic agent in those patients with newly diagnosed high-risk neuroblastoma as part of the conditioning regimen for myeloablative chemotherapy (MAC).Objective:To evaluate the feasibility of upfront consolidation treatment with 131I-mIBG plus MAC and hematopoietic stem cell transplantation (HSCT) in high-risk neuroblastoma patients.Methods:A retrospective, single-center study was conducted from 2003-2019 on newly diagnosed high-risk neuroblastoma patients without progressive disease (PD) after the completion of induction therapy. They received 131I-mIBG infusion and MAC followed by HSCT.Results:A total of 24 high-risk neuroblastoma patients were enrolled with a median age of 3.0 years at diagnosis. After receiving this sequential consolidation treatment, 3 of 13 patients who were in partial response (PR) before 131I-mIBG treatment achieved either complete response (CR) (n = 1) or very good partial response (VGPR) (n = 2) after HSCT. With a median follow-up duration of 13.0 months after 131I-mIBG therapy, the 5-year event-free survival and overall survival rates estimated were 29% and 38% for the entire cohort, and 53% and 67% for the patients who were in CR/VGPR at the time of 131I-mIBG treatment.Interpretation:Upfront consolidation treatment with 131I-mIBG plus MAC and HSCT is feasible and tolerable in high-risk neuroblastoma patients, however the survival benefit of this 131I-mIBG regimen is only observed in the patients who were in CR/VGPR at the time of 131I-mIBG treatment.

简介：无

简介：Objective:ToevaluatethefeasibilityofDNAimagecytometry(DNA-ICM)asaprimaryscreeningmethodforesophagealsquamouscellcancer(ESCC).Methods:Atotalof5,382localresidentsaged40–69yearsfromthreehigh-riskareasinChina(LinzhouinHenanprovince,FeichenginShandongprovinceandCixianinHebeiprovince)from2008to2011wererecruitedinthispopulation-basedscreeningstudy.And2,526subjectsdeclinedtoreceiveendoscopicbiopsyexaminationwithLugol'siodinestaining,while9and815subjectswereexcludedfromliquid-basedcytologyandDNA-ICMtestrespectivelyduetoslidequality.Finally,2,856,5,373and4,567subjectswereenrolledintheanalysisforendoscopicbiopsyexamination,liquid-basedcytologyandDNA-ICMtest,respectively.Sensitivity(SE),specificity(SP),negativepredictivevalues(NPV)andpositivepredictivevalues(PPV)aswellastheir95%confidenceintervals(95%CI)forDNA-ICM,liquid-basedcytologyandthecombinationofthetwomethodswerecalculated.Receiveroperatingcharacteristic(ROC)curveswereappliedtodeterminethecutoffpointofDNA-ICMforesophagealcancer.Results:DNA-ICMresultsweresignificantlycorrelativewithesophagealcancerandprecancerlesions(χ~2=18.016,P<0.001).Thecutoffpointswere5,802,5,803and8,002basedondissimilarpathologicaltypesoflowgradeintraepithelialneoplasia(LGIN),highgradeintraepithelialneoplasia(HGIN),andESCC,respectively,and5,803waschoseninthisstudyconsideringtheSEandSP.TheSE,SP,PPV,NPVofDNA-ICMtest(cutoffpoint5,803)combinedwithliquid-basedcytology[thresholdatypicalsquamouscellsofundeterminedsignificance(ASCUS)]wereseparately72.1%(95%CI:70.3%-73.9%),43.3%(95%CI:41.3%-45.3%),22.8%(95%CI:21.1%-24.5%)and87.0%(95%CI:85.7%-88.3%)forLGIN,85.7%(95%CI:84.3%-87.1%),41.3%(95%CI:39.3%-43.3%),4.6%(95%CI:3.8%-5.4%)and98.9%(95%CI:98.5%-99.3%)forHGIN,and96.0%(95%CI:95.2%-96.8%),40.8%(95%CI:38.8%-42.8%),1.7%(95%CI:1.2%-2.2%)and99.9%

简介：我们与高风险的前列腺癌症在271个病人报导全面的率，地点和积极外科的边缘(PSM)的预兆的因素。在2008年4月和2011年10月之间，我们有希望地从作为D'Amico分类的病人收集了数据高风险经历了帮助机器人的laparoscopic激进分子前列腺切除术。PSM的全面的率和地点被报导。逐步的逻辑回归模型被适合估计PSM的预兆的因素。PSM的全面的率是25.1%(271个病人中的68个)。这些PSM，(68中的26个)38.2%是posterolateral(PL)，26.5%(68中的18个)multifocal，16.2%(68中的11个)在顶，14.7%(68中的10个)在膀胱颈，并且4.4%(3/68)在另外的地点。有病理学的阶段pT2的病人的PSM率是8.6%(140中的12个)，26.6%(64中的17个)pT3a，53.3%(32/60)pT4的pT3b，和100%(7中的7个)。在包括pre-，intra-，和手术后的参数的一个逻辑回归模型，身体团索引(机会比率[或]：1.09；95%信心间隔[CI]：1.01-1.19，P=0.029)，病理学的舞台(pT3b或更高对pT2；或：5.14；95%CI：1.92-13.78；P=0.001)并且肿瘤的百分比(或：46.71；95%CI：6.37-342.57；P<0.001)是为PSM的独立预兆的因素。在病人在的PSM的最普通的地点高风险是PL方面，它反映报导肿瘤攻击性。PSM的唯一的重要预兆的因素是病理学的结果，例如在标本和病理学的舞台的肿瘤的百分比。

简介：为在激进的前列腺切除术以后的高风险的局部性的前列腺癌症的辅助神经质的治疗和优化政体的角色仍然保持争论。此处，临床的试用CU1005有希望地评估了最大的雄激素阻塞或bicalutamide的二政体象为高风险的局部性的前列腺癌症的立即的辅助治疗每日的150mg。总的来说，而102收到了9月辅助bicalutamide，209个连续病人在这研究，其中107收到了9月辅助最大的雄激素阻塞，被招募150mg。中部的手术后的后续时间是27.0个月。主要端点是生物化学的复发。209个病人，59个病人开发了生物化学的复发。关于临床的特征的二个组之间没有差别，包括年龄，预告的处理前列腺特定的抗原，格利森分数，外科的边缘地位，或病理学的阶段。最大的雄激素阻塞组经历了更长生物化学的没有复发的幸存(P=0.004)与bicalutamide相比150mg组。在二个组的副作用是类似的并且能中等在所有病人被容忍。在结论，立即的、9月的最大的雄激素阻塞应该作为辅助治疗作为bicalutamide的一种选择被认为150mg为在激进的前列腺切除术以后的高风险的局部性的前列腺癌症病人。

简介：